4549 On Other Exchanges
Symbol
Exchange
4549 is not on other exchanges.

eiken chemical co ltd (4549) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EIKEN CHEMICAL CO LTD (4549)
\

Related News

No related news articles were found.

eiken chemical co ltd (4549) Related Businessweek News

No Related Businessweek News Found

eiken chemical co ltd (4549) Details

Eiken Chemical Co., Ltd. manufactures and sells clinical diagnostics and equipment in Japan. The company is involved in developing clinical diagnostic aids to various aspects of contemporary medicine, including biochemical, immunological, serological, dry chemical diagnosis, and automatic analyzers. It also develops and supplies OC-SENSOR, an automated immunochemical fecal test for detecting gastrointestinal bleeding associated with disorders, such as colorectal cancer, polyps, and diverticulitis. In addition, the company offers real-time turbid meters, and homeothermal equipment; amplification kits and fluorescence detection reagents for research use; and detection kits for food and environment inspection. Further, it manufactures a range of products that are used in the field of microbiology; and provides other products comprising immunological and serological reagents, including IVDs and POCT devices. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was founded in 1939 and is headquartered in Tokyo, Japan.

694 Employees
Last Reported Date: 06/23/17
Founded in 1939

eiken chemical co ltd (4549) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eiken chemical co ltd
Eiken Chemical Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Announces Dividend for the Six Months Ended September 30, 2017, Payable on December 1, 2017; Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018

Eiken Chemical Co., Ltd. announced consolidated earnings results for the six months ended September 30, 2017. For the six months, the company reported net sales of JPY 17,462 million against JPY 16,804 million a year ago. Operating income was JPY 2,215 million against JPY 2,325 million a year ago. Ordinary income was JPY 2,255 million against JPY 2,343 million a year ago. Net income attributable to shareholders of parent company was JPY 1,633 million against JPY 1,715 million a year ago. Diluted net income per was JPY 88.15 against JPY 92.67 a year ago. Profit before income taxes was JPY 2,249 million against JPY 2,322 million a year ago. The company announced a dividend of JPY 25.00 per share for the six months ended September 30, 2017, compared with JPY 20.00 per share a year ago. The scheduled date of dividend payment is December 1, 2017. The company expects to pay a year-end dividend of JPY 25.00 per share for the fiscal year ending March 2018, compared with JPY 30.00 per share for the fiscal year ended March 2017. The company provided consolidated earnings guidance for the fiscal year ending March 31, 2018. For the full year, the company expects net sales of JPY 35,840 million, operating income of JPY 3,070 million, ordinary income of JPY 3,070 million, and net income attributable to shareholders of parent company of JPY 2,180 million or JPY 119.00 per share.

Eiken Chemical Co., Ltd., Q2 2018 Earnings Call, Oct 25, 2017

Eiken Chemical Co., Ltd., Q2 2018 Earnings Call, Oct 25, 2017

Eiken Chemical Co., Ltd. Revised Consolidated and Non Consolidated Earnings Guidance for the First Six Months of Fiscal Year Ending September 30, 2017

Eiken Chemical Co., Ltd. revised consolidated and non consolidated earnings guidance for the first six months of fiscal year ending September 30, 2017. For the period, the consolidated basis, company excepts expects operating income of ¥2,280 million, ordinary income of ¥2,310 million and net income attributable to shareholders of parent company of ¥1,680 million or ¥91.71 per share on net sales of ¥17,600 million compared to operating income of ¥1,400 million, ordinary income of ¥1,400 million and net income attributable to shareholders of parent company of ¥1,000 million or ¥54.60 per share on net sales of ¥18,000 million as previously forecasted. For the period, the non-consolidated basis, company excepts expects operating income of ¥2,320 million, ordinary income of ¥2,340 million and net income of ¥1,700 million or ¥92.80 per share on net sales of ¥17,600 million compared to operating income of ¥1,450 million, ordinary income of ¥1,450 million and net income of ¥1,050 million or ¥57.33 per share on net sales of ¥17,920 million as previously forecasted. Reason for Revision: Sales: Regarding overseas sales, although it is expected to increase compared to the previous fiscal year, it is expected to be lower than initially forecast due to sluggish sales of fecal immunochemical test reagents and LAMP reagent sales. Regarding domestic sales, it is expected as originally anticipated. Profit will significantly increase due to that the development cost-about ¥750 million of the compact fully automated genetic testing device scheduled in this second quarter consolidated accounting period will be carried over to the fourth quarter, and also the cost reduction by efficient use.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4549 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4549.
View Industry Companies
 

Industry Analysis

4549

Industry Average

Valuation 4549 Industry Range
Price/Earnings 30.8x
Price/Sales 2.5x
Price/Book 2.7x
Price/Cash Flow 36.1x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EIKEN CHEMICAL CO LTD, please visit www.eiken.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.